Company Encyclopedia
View More
name
Atea Pharmaceuticals
AVIR.US
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc.
4.514 T
AVIR.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Atea Pharmaceuticals to Present at Evercore Healthcare Conference

    Atea Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on December 3, 2025, in Coral Gables, Florida. The presentation will feature CEO Jean-Pierre Sommadossi and other management team members.

    Reuters·
    US
    AVIR
    0.00%
    Reuters·
    US
    AVIR
    0.00%

    Atea Pharmaceuticals’ Earnings Call Highlights Progress and Optimism

    Atea Pharmaceuticals' Q3 earnings call highlighted progress in their HCV Phase III program, strong financial health, and promising research findings. Despite increased R&D expenses and decreased interest income, the company remains optimistic due to strategic advancements and financial stability. Key developments include the CBEYOND and Sea Forward trials, new research on bemifovir, and pipeline expansion to hepatitis E. Atea's robust financial position supports ongoing initiatives, with patient enrollment and results expected by 2026.

    Tip Ranks·
    US
    AVIR
    0.00%
    Tip Ranks·
    US
    AVIR
    0.00%

    Atea Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q3 EPS resutls.

    benzinga_article·
    US
    AVIR
    0.00%
    benzinga_article·
    US
    AVIR
    0.00%

    Atea Pharmaceuticals | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    AVIR
    0.00%
    LB filings·
    US
    AVIR
    0.00%

    Atea Pharmaceuticals | 8-K: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    AVIR
    0.00%
    LB filings·
    US
    AVIR
    0.00%
    © 2025 Longbridge｜Disclaimer